keyword
https://read.qxmd.com/read/38632238/tak1-inhibition-leads-to-ripk1-dependent-apoptosis-in-immune-activated-cancers
#21
JOURNAL ARTICLE
Helene Damhofer, Tülin Tatar, Benjamin Southgate, Scott Scarneo, Karl Agger, Daria Shlyueva, Lene Uhrbom, Gillian M Morrison, Philip F Hughes, Timothy Haystead, Steven M Pollard, Kristian Helin
Poor survival and lack of treatment response in glioblastoma (GBM) is attributed to the persistence of glioma stem cells (GSCs). To identify novel therapeutic approaches, we performed CRISPR/Cas9 knockout screens and discovered TGFβ activated kinase (TAK1) as a selective survival factor in a significant fraction of GSCs. Loss of TAK1 kinase activity results in RIPK1-dependent apoptosis via Caspase-8/FADD complex activation, dependent on autocrine TNFα ligand production and constitutive TNFR signaling...
April 17, 2024: Cell Death & Disease
https://read.qxmd.com/read/38632203/adverse-events-of-nivolumab-plus-ipilimumab-versus-nivolumab-plus-cabozantinib-a-real-world-pharmacovigilance-study
#22
JOURNAL ARTICLE
Yurie Oka, Jun Matsumoto, Tatsuaki Takeda, Naohiro Iwata, Takahiro Niimura, Aya Fukuma Ozaki, Kensuke Bekku, Hirofumi Hamano, Motoo Araki, Keisuke Ishizawa, Yoshito Zamami, Noritaka Ariyoshi
BACKGROUND: No head-to-head clinical trials have compared the differences in adverse events (AEs) between nivolumab plus ipilimumab (NIVO-IPI) and nivolumab plus cabozantinib (NIVO-CABO) in the treatment of metastatic renal cell carcinoma (mRCC). AIM: We analysed the two largest real-world databases, the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the World Health Organization's VigiBase, to elucidate the differences in AEs between NIVO-IPI and NIVO-CABO...
April 17, 2024: International Journal of Clinical Pharmacy
https://read.qxmd.com/read/38631651/transient-receptor-potential-vanilloid-1-trpv1-channels-act-as-suppressors-of-the-growth-of-glioma
#23
JOURNAL ARTICLE
Jingjing Cheng, Mengliu Zeng, Biwen Peng, Ping Li, ShiYu Zhao
The aim of this study was to investigate the expression and function of the transient receptor potential vanilloid 1 (TRPV1) in glioma. We found that the expression of TRPV1 mRNA and protein were upregulated in glioma compared with normal brain by qPCR and western blot analysis. In order to investigate the function of TRPV1 in glioma, short hairpin RNA (shRNA) and the inhibitor of TRPV1 were used. In vitro, the activation of TRPV1 induced cell apoptosis with decreased migration capability and inhibited proliferation, which was abolished upon TRPV1 pharmacological inhibition and silencing...
April 15, 2024: Brain Research Bulletin
https://read.qxmd.com/read/38631503/the-antidiabetic-drug-ipragliflozin-induces-vasorelaxation-of-rabbit-femoral-artery-by-activating-a-kv-channel-the-serca-pump-and-the-pka-signaling-pathway
#24
JOURNAL ARTICLE
Minju Park, Seo-Yeong Mun, Wenwen Zhuang, Junsu Jeong, Hye Ryung Kim, Hongzoo Park, Eun-Taek Han, Jin-Hee Han, Wanjoo Chun, Hongliang Li, Won Sun Park
We explored the vasorelaxant effects of ipragliflozin, a sodium-glucose cotransporter-2 inhibitor, on rabbit femoral arterial rings. Ipragliflozin relaxed phenylephrine-induced pre-contracted rings in a dose-dependent manner. Pre-treatment with the ATP-sensitive K+ channel inhibitor glibenclamide (10 μM), the inwardly rectifying K+ channel inhibitor Ba2+ (50 μM), or the Ca2+ -sensitive K+ channel inhibitor paxilline (10 μM) did not influence the vasorelaxant effect. However, the voltage-dependent K+ (Kv) channel inhibitor 4-aminopyridine (3 mM) reduced the vasorelaxant effect...
April 15, 2024: European Journal of Pharmacology
https://read.qxmd.com/read/38631435/in-vitro-and-in-vivo-exposure-of-endothelial-cells-to-dibutyl-phthalate-promotes-monocyte-adhesion
#25
JOURNAL ARTICLE
Dunja Kokai, Jelena Markovic Filipovic, Marija Opacic, Ivana Ivelja, Vojislav Banjac, Bojana Stanic, Nebojsa Andric
The effect of endothelial cells' exposure to dibutyl phthalate (DBP) on monocyte adhesion is largely unknown. We evaluated monocyte adhesion to DBP-exposed endothelial cells by combining three approaches: short-term exposure (24 h) of EA.hy926 cells to 10-6 , 10-5 , and 10-4 M DBP, long-term exposure (12 weeks) of EA.hy926 cells to 10-9 , 10-8 , and 10-7 M DBP, and exposure of rats (28 and 90 days) to 100, 500, and 5000 mg DBP/kg food. Monocyte adhesion to human EA.hy926 and rat aortic endothelial cells, expression of selected cellular adhesion molecules and chemokines, and the involvement of extracellular signal-regulated kinase 1/2 (ERK1/2) were analyzed...
April 15, 2024: Food and Chemical Toxicology
https://read.qxmd.com/read/38631176/ntrk-rearranged-spindle-cell-neoplasm-initial-observation-of-imaging-appearance-and-clinicopathologic-correlation
#26
JOURNAL ARTICLE
Matthew Spano, Cecilia Davis-Hayes, Meera Hameed, Ryma Benayed, Sinchun Hwang
OBJECTIVE: To explore pre-treatment imaging findings of neurotrophic tyrosine receptor kinase (NTRK)-rearranged spindle cell neoplasm, an emerging group of molecularly defined soft tissue tumors and summarize the clinical course, including TRK inhibitor therapy response. MATERIALS AND METHODS: This retrospective study included 8 women and 4 men with NTRK-rearranged spindle cell neoplasm (median age, 35.5 years, range, 0-66). Available pre-treatment MRI, CT, PET, and US imaging were reviewed...
March 22, 2024: Clinical Imaging
https://read.qxmd.com/read/38631104/real-world-analysis-of-peritoneal-metastasis-from-renal-cell-carcinoma-meet-uro27
#27
JOURNAL ARTICLE
Marco Stellato, Sebastiano Buti, Marco Maruzzo, Maria Bassanelli, Melissa Bersanelli, Marilena Di Napoli, Michele Dionese, Martina Fanelli, Roberto Filippi, Giuseppe Fotia, Luca Galli, Francesco Grillone, Michele Maffezzoli, Brigida Anna Maiorano, Cecilia Nasso, Sara Elena Rebuzzi, Luca Lalli, Giandomenico Roviello, Mariella Sorarù, Bruno Vincenzi, Giuseppe Procopio, Elena Verzoni
BACKGROUND: Peritoneal metastases (PM) have been reported in approximately 1% of patients with metastatic Renal Cell Carcinoma (mRCC). Outcome data are limited due to the rarity of this metastatic site. Therefore, the aim of our study is to describe renal cell carcinoma (RCC) patients with PM treated as per clinical practice. MATERIALS AND METHODS: Baseline characteristics and outcome data of patients with PM from RCC were retrospectively collected from 18 Italian oncological referral centers adhering to the Meet-Uro group, from January 2016 to January 2023...
March 19, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38631036/what-doesn-t-fit-is-made-to-fit-pim-1-kinase-adapts-to-the-configuration-of-stilbene-based-inhibitors
#28
JOURNAL ARTICLE
Phil M M Hochban, Lukas Heyder, Andreas Heine, Wibke E Diederich
Recently, we have developed novel Pim-1 kinase inhibitors starting from a dihydrobenzofuran core structure using a computational approach. Here, we report the design and synthesis of stilbene-based Pim-1 kinase inhibitors obtained by formal elimination of the dihydrofuran ring. These inhibitors of the first design cycle, which were obtained as inseparable cis/trans mixtures, showed affinities in the low single-digit micromolar range. To be able to further optimize these compounds in a structure-based fashion, we determined the X-ray structures of the protein-ligand-complexes...
April 17, 2024: Archiv der Pharmazie
https://read.qxmd.com/read/38630705/lysophosphatidic-acid-down-regulates-human-ripk4-mrna-in-keratinocyte-derived-cell-lines
#29
JOURNAL ARTICLE
Lei Xu, Peter Bajorski, Brian Poligone
The tight control of proliferating keratinocytes is vital to the successful function of the skin. Differentiation of dividing cells is necessary to form a skin barrier. The same dividing cells are necessary to heal wounds and when malignant form tumors. RIPK4, a serine-threonine kinase, plays critical roles in these processes. Its loss of function was associated with pathological keratinocyte proliferation and development of squamous cell carcinoma (SCC) in humans and mice. The current study extends previous findings in the importance of RIPK4 in keratinocyte proliferation...
2024: PloS One
https://read.qxmd.com/read/38630555/overcoming-osimertinib-resistance-with-akt-inhibition-in-egfrm-driven-non-small-cell-lung-cancer-with-pik3ca-pten-alterations
#30
JOURNAL ARTICLE
Ursula Grazini, Aleksandra Markovets, Lucy Ireland, Daniel O'Neill, Benjamin Phillips, Man Xu, Matthias Pfeifer, Tereza Vaclova, Matthew J Martin, Ludovic Bigot, Luc Friboulet, Ryan Hartmaier, Maria Emanuela Cuomo, Simon T Barry, Paul D Smith, Nicolas Floc'h
PURPOSE: Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) indicated for the treatment of EGFR mutated (EGFRm)-driven lung adenocarcinomas. Osimertinib significantly improves progression-free survival in first-line treated patients with EGFRm advanced NSCLC. Despite the durable disease control, the majority of patients receiving osimertinib eventually develop disease progression. EXPERIMENTAL DESIGN: ctDNA profiling analysis on-progression plasma samples from patients treated with osimertinib in both first (Phase 3, FLAURA trial) and second-line trials (Phase 3, AURA3 trial) revealed a high prevalence of PIK3CA/AKT/PTEN alterations...
April 17, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38630549/navigating-resistance-to-alk-inhibitors-in-the-lorlatinib-era-a-comprehensive-perspective-on-nsclc
#31
REVIEW
Maria Gemelli, Adriana Albini, Gianpiero Catalano, Matteo Incarbone, Maria Cannone, Emanuela Balladore, Riccardo Ricotta, Giuseppe Pelosi
INTRODUCTION: The emergence of anaplastic lymphoma kinase (ALK) rearrangements in non-small cell lung cancer (NSCLC) has revolutionized targeted therapy. This dynamic landscape, featuring novel ALK inhibitors and combination therapies, necessitates a profound understanding of resistance mechanisms for effective treatment strategies. Recognizing two primary categories - on-target and off-target resistance - underscores the need for comprehensive assessment. AREAS COVERED: This review delves into the intricacies of resistance to ALK inhibitors, exploring complexities in identification and management...
April 17, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38630440/design-synthesis-and-biological-evaluation-of-%C3%AE-trifluoroethoxydimethyl-selenides-as-potent-antiosteoporosis-agents
#32
JOURNAL ARTICLE
Yao Wu, Bin Li, Linkun Ying, Yao Chen, Yuxin Zhang, Chaoming Hu, Yichi Zhang, Lele Yi, Weiwei Xue, Shengbin Huang, Zengqiang Song
An efficient protocol for the synthesis of β-trifluoroethoxydimethyl selenides was achieved under mild reaction conditions, and 39 compounds were prepared. All compounds were evaluated for their abilities to inhibit RANKL-induced osteoclastogenesis, compound 4aa exhibited the most potent activity. Further investigations revealed that 4aa could inhibit F-actin ring generation, bone resorption, and osteoclast-specific gene expression in vitro . Western blot analyses demonstrated that compound 4aa abrogated the RANKL-induced mitogen-activated protein kinase and NF-kB-signaling pathways...
April 17, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38630392/pi3k-akt-mtor-signaling-pathway-an-important-driver-and-therapeutic-target-in-triple-negative-breast-cancer
#33
REVIEW
Huan-Ping Zhang, Rui-Yuan Jiang, Jia-Yu Zhu, Ke-Na Sun, Yuan Huang, Huan-Huan Zhou, Ya-Bing Zheng, Xiao-Jia Wang
Triple-negative breast cancer (TNBC) is a highly heterogeneous tumor lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. It has higher aggressiveness and metastasis than other subtypes, with limited effective therapeutic strategies, leading to a poor prognosis. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway is prevalently over-activated in human cancers and contributes to breast cancer (BC) growth, survival, proliferation, and angiogenesis, which could be an interesting therapeutic target...
April 17, 2024: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://read.qxmd.com/read/38630325/chlordiazepoxide-against-signalling-receptor-and-regulatory-proteins-of-breast-cancer-a-structure-based-in-silico-approach
#34
JOURNAL ARTICLE
Ahad Amer Alsaiari, Amal F Gharib, Maha Mahfouz Bakhuraysah, Amani A Alrehaili, Shatha M Algethami, Hayfa Ali Alsaif, Norah Al Harthi, Mohammed Ageeli Hakami
Among the most prevalent forms of cancer are breast, lung, colon-rectum, and prostate cancers, and breast cancer is a major global health challenge, contributing to 2.26 million cases with approximately 685,000 deaths worldwide in 2020 alone, typically beginning in the milk ducts or lobules that produce and transport milk during lactation and it is becoming challenging to treat as the tissues are developing resistance, which makes urgent calls for new multitargeted drugs. The multitargeted drug design provides a better solution, simultaneously targeting multiple pathways, even when the drug resists one, it remains effective for others...
April 17, 2024: Medical Oncology
https://read.qxmd.com/read/38629656/a-structure-activity-investigation-of-the-fungal-metabolite-tan-2483b-inhibition-of-bruton-s-tyrosine-kinase
#35
JOURNAL ARTICLE
Jordan McCone, Paul H Teesdale-Spittle, Jack U Flanagan, Joanne E Harvey
The natural product (-)-TAN-2483B is a fungal secondary metabolite which displays promising anti-cancer and immunomodulatory activity. Our previous syntheses of (-)-TAN-2483B and sidechain analogues uncovered inhibitory activity against Bruton's tyrosine kinase (Btk), an established drug target for various leukaemia and immunological diseases. A structure-based computational study using ensemble docking and molecular dynamics was performed to determine plausible binding modes for (-)-TAN-2483B and analogues in the Btk binding site...
April 17, 2024: Chemistry: a European Journal
https://read.qxmd.com/read/38629639/novel-germline-jak2-r715t-mutation-causing-pv-like-erythrocytosis-in-3-generations-amelioration-by-ropeg-interferon
#36
JOURNAL ARTICLE
Jihyun Song, Lucie Lanikova, Soo Jin Kim, Nicolas Papadopoulos, Jessica Meznarich, Stefan N Constantinescu, Brynn Parsegov, Jaroslav F Prchal, Josef T Prchal
Polycythemia vera (PV) is a clonal disorder arising from the acquired somatic mutations of the JAK2 gene, including JAK2V617F or several others in exon 12. A 38-year-old female had a stroke at age 32 and found to have elevated hemoglobin, normal leukocytes, normal platelets, and tested negative for JAK2V617F and exon 12 mutations. Next generation sequencing revealed a novel mutation: JAK2R715T in the pseudokinase domain (JH2) at 47.5%. Its presence in her nail DNA confirmed a germline origin. Her mother and her son similarly had erythrocytosis and a JAK2R715T mutation...
April 17, 2024: American Journal of Hematology
https://read.qxmd.com/read/38629388/long-term-administration-of-royal-jelly-regulates-age-related-disorders-and-improves-gut-function-in-naturally-aging-mice
#37
JOURNAL ARTICLE
Lili Chen, Li Zhao, Gaowei Zhang, Zhuozhen Li, Liangliang Qu, Liping Luo
A natural aging mouse model can exhibit physiological characteristics that closely resemble those of human aging. Through long-term observation, it reflects the occurrence and development of the aging process more accurately. Although numerous beneficial effects of royal jelly (RJ) have been extensively demonstrated in multiple experimental models, the effects of RJ on naturally aging mice have not yet been investigated. In this study, middle-aged male C57BL/6J mice were given RJ for 9 consecutive months to investigate its impact on the intestinal barrier function, gut microbiota, short-chain fatty acids (SCFAs) content and possible mechanisms...
April 17, 2024: Food & Function
https://read.qxmd.com/read/38629385/role-of-non-receptor-tyrosine-kinases-in-epilepsy-significance-and-potential-as-therapeutic-targets
#38
REVIEW
Ozasvi R Shanker, Sonali Kumar, Jyotirmoy Banerjee, Manjari Tripathi, P Sarat Chandra, Aparna Banerjee Dixit
INTRODUCTION: Epilepsy is a chronic neurological condition characterized by a persistent propensity for seizure generation. About one-third of patients do not achieve seizure control with the first-line treatment options, which include > 20 antiseizure medications. It is therefore imperative that new medications with novel targets and mechanisms of action are developed. AREAS COVERED: Clinical studies and preclinical research increasingly implicate Non-receptor tyrosine kinases (nRTKs) in the pathogenesis of epilepsy...
April 17, 2024: Expert Opinion on Therapeutic Targets
https://read.qxmd.com/read/38629293/current-treatment-and-novel-insights-regarding-ros1-targeted-therapy-in-malignant-tumors
#39
REVIEW
Shizhe Li, He Zhang, Ting Chen, Xiaowen Zhang, Guanning Shang
BACKGROUND: The proto-oncogene ROS1 encodes an intrinsic type I membrane protein of the tyrosine kinase/insulin receptor family. ROS1 facilitates the progression of various malignancies via self-mutations or rearrangements. Studies on ROS1-directed tyrosine kinase inhibitors have been conducted, and some have been approved by the FDA for clinical use. However, the adverse effects and mechanisms of resistance associated with ROS1 inhibitors remain unknown. In addition, next-generation ROS1 inhibitors, which have the advantage of treating central nervous system metastases and alleviating endogenous drug resistance, are still in the clinical trial stage...
April 2024: Cancer Medicine
https://read.qxmd.com/read/38629245/raf1-gene-fusions-are-recurrent-driver-events-in-infantile-fibrosarcoma-like-mesenchymal-tumors
#40
JOURNAL ARTICLE
Marialetizia Motta, Sabina Barresi, Simone Pizzi, Delfina Bifano, Jennifer Lopez Marti, Marta Garrido-Pontnou, Elisabetta Flex, Alessandro Bruselles, Isabella Giovannoni, Giovannina Rotundo, Alessandra Fragale, Valentina Tirelli, Silvia Vallese, Andrea Ciolfi, Gianni Bisogno, Rita Alaggio, Marco Tartaglia
Infantile fibrosarcomas (IFS) and congenital mesoblastic nephroma (CMN) are rare myofibroblastic tumors of infancy and early childhood commonly harboring the ETV6::NTRK3 gene fusion. IFS/CMN are considered as tumors with an 'intermediate prognosis' as they are locally aggressive, but rarely metastasize, and generally have a favorable outcome. A fraction of IFS/CMN-related neoplasms are negative for the ETV6::NTRK3 gene rearrangement and are characterized by other chimeric proteins promoting MAPK signaling upregulation...
April 17, 2024: Journal of Pathology
keyword
keyword
70541
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.